Headache News and Research

Latest Headache News and Research

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Sucampo Pharmaceuticals, Inc. today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

12 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Concussion: an interview with Dr Rob Reid

Concussion happens when something produces a concussive force to the head, such as a blow to the head. The definition from the 2008 consensus, which was in Zurich, is, “concussion is defined as a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces.”

10 Sep 2012

All kids are susceptible to concussions

The gridiron is back in action. From little leagues to professional teams, football frenzy has begun, and with it, concerns about concussions. But it's not just jarring tackles that can lead to concussions in kids. According to Dr. Ryan Coates, pediatric neurologist at Loyola University Health System, there are many ways kids are exposed to concussion risks.

6 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Boehringer Ingelheim presented today the first data from the Phase III UniTinA-asthma program. In two studies, presented at the 2012 European Respiratory Society (ERS) Congress in Vienna, Austria, tiotropium delivered once daily via the Respimat inhaler significantly improved lung function and reduced asthma exacerbations in patients who remained symptomatic on current treatment with at least high dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).

3 Sep 2012

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Renal denervation improves depression, QOL and stress in patients with resistant hypertension

Renal sympathetic denervation improves anxiety, depression, quality of life and stress in patients with resistant hypertension, according to research presented at ESC Congress 2012 by Dr Denise Fischer from Saarland University Hospital.

27 Aug 2012

Children more likely to pick up stomach infections from private water supplies

Children drinking from around half the UK's private water supplies are almost five times more likely to pick up stomach infections - according to research from the University of East Anglia (UEA).

26 Aug 2012

Guidelines for parents to beat back-to-school bugs

School bells are beginning to sound again across the country, so it will only be a matter of time until every parent comes face-to-face with a child who wakes up with a cold, fever or upset stomach.

24 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

Healthcare announces important changes to the U.S. product label for Optison

GE Healthcare today announced important changes to the U.S. product label for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.

22 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

CDC reports worst West Nile virus outbreak in the U.S.

This past year's mild winter and wet spring could be contributing to the worst West Nile virus outbreak since the disease was first detected in the United States in 1999. According to the Centers for Disease Control and Prevention, there have been more cases of the virus so far this year than any year. As of August 14, almost 700 cases had been reported across the nation, including 26 deaths. This year also marks the earliest reported case of West Nile virus in New Jersey.

18 Aug 2012

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.

18 Aug 2012

Headache News and Research

Latest Headache News and Research

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Concussion: an interview with Dr Rob Reid

All kids are susceptible to concussions

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

First data from Boehringer Ingelheim’s Respimat Phase III asthma program

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Novartis receives EC approval for Jakavi to treat myelofibrosis

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Renal denervation improves depression, QOL and stress in patients with resistant hypertension

Children more likely to pick up stomach infections from private water supplies

Guidelines for parents to beat back-to-school bugs

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

Healthcare announces important changes to the U.S. product label for Optison

Enzalutamide extends castration-resistant prostate cancer survival

CDC reports worst West Nile virus outbreak in the U.S.

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in